Mineralocorticoid receptor antagonists, commonly called MRAs, are a class of drugs that block the hormone aldosterone from binding to its receptor, reducing fluid retention, lowering blood pressure, and protecting the heart and kidneys from inflammatory damage. They are prescribed for heart failure, resistant high blood pressure, chronic kidney disease in people with type 2 diabetes, and fluid buildup from liver cirrhosis, among other conditions. Though the oldest MRA, spironolactone, has been available since the early 1960s, newer drugs in this class have expanded who can benefit and reduced some of the more bothersome side effects.
How MRAs Work
Aldosterone is a hormone made by the adrenal glands. Its primary job is telling the kidneys to hold onto sodium and water while excreting potassium. That is useful in small bursts, like when you are dehydrated, but chronically high aldosterone activity drives up blood pressure, promotes fluid overload, and causes direct damage to the heart, blood vessels, and kidneys. MRAs sit in the aldosterone receptor and prevent the hormone from activating it.
The benefits go well beyond just flushing out extra fluid. Research has shown that when the mineralocorticoid receptor is activated, it triggers oxidative stress, vascular inflammation, and tissue fibrosis through multiple signaling pathways, including the plasminogen activation system and angiotensin II signaling.1PubMed Central. Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation Blocking that receptor reduces the scarring and stiffening that gradually destroy heart and kidney tissue. This is why MRAs improve outcomes in heart failure even in patients whose aldosterone levels are not particularly elevated.
Types of MRAs
MRAs fall into two broad categories based on their chemical structure: steroidal and nonsteroidal. Most of the clinical experience to date comes from the steroidal agents, but the nonsteroidal category is growing fast.
Steroidal MRAs
Spironolactone was the first MRA to reach clinical use. It blocks the mineralocorticoid receptor effectively, but because its structure resembles other steroid hormones, it also binds to androgen and progesterone receptors. That cross-reactivity is the main reason spironolactone causes side effects like breast tenderness and enlargement in men, menstrual irregularities in women, and reduced libido. Eplerenone, approved later, was designed to be more selective for the mineralocorticoid receptor and causes far fewer hormonal side effects, though it is also somewhat less potent at blocking aldosterone.
Nonsteroidal MRAs
Finerenone is the leading nonsteroidal MRA and the most studied in this newer class. Because its chemical backbone is not steroid-based, it does not interact meaningfully with androgen or progesterone receptors, which essentially eliminates the hormonal side effects that trouble many spironolactone users.2PubMed Central. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine Finerenone also distributes differently in the body compared with spironolactone and eplerenone: it concentrates more in the heart and kidneys and less in the kidneys alone, which may explain some of its distinctive benefits for cardiovascular protection in people with diabetic kidney disease. Several other nonsteroidal MRAs are in clinical trials, but finerenone is the only one with large-scale outcome data so far.
Heart Failure
Heart failure is the condition where MRAs have the deepest evidence base. Spironolactone was first shown to improve survival in patients with severe heart failure and a reduced pumping ability, and eplerenone later extended those benefits to people with milder symptoms and to those who developed heart failure after a heart attack.3PubMed. Mineralocorticoid Receptor Antagonists in Heart Failure: An Update
A large individual-patient-level meta-analysis published in The Lancet quantified these effects across thousands of patients. In trials of people with reduced pumping ability, MRAs cut heart failure hospitalizations by roughly a third, cardiovascular deaths by about 28%, and all-cause deaths by about 27%. In trials of people whose pumping ability was only mildly reduced or preserved, MRAs still cut hospitalizations significantly, by about 18%, but did not produce a clear reduction in cardiovascular death or overall death.4The Lancet. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis Another meta-analysis of randomized trials found a similar pattern, confirming significant mortality benefits in heart failure with reduced ejection fraction and hospitalization benefits extending to the broader heart failure population.5PubMed Central. Efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a meta-analysis of randomized controlled trials
MRAs are now considered part of the foundational drug regimen for heart failure with reduced ejection fraction, alongside other drug classes. A network meta-analysis found that the combination of a neprilysin inhibitor, a beta-blocker, an MRA, and an SGLT2 inhibitor was the most effective regimen for reducing a composite of cardiovascular death and heart failure hospitalization in patients with mildly reduced or preserved ejection fraction, cutting the risk by roughly half compared to placebo.6PubMed. Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction: Systematic Review and Network Meta-Analysis
Resistant High Blood Pressure
If your blood pressure stays above target despite taking three or more medications at adequate doses, including a diuretic, you have what doctors call resistant hypertension. Spironolactone has become the go-to add-on drug for this situation. A landmark crossover trial, PATHWAY-2, found that spironolactone lowered home systolic blood pressure by about 9 mmHg more than placebo and about 4 mmHg more than either doxazosin or bisoprolol, the two main alternatives tested.7The Lancet. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
A systematic review and meta-analysis of multiple trials confirmed the benefit, finding that spironolactone reduced office systolic blood pressure by about 20 mmHg compared with placebo and lowered 24-hour ambulatory systolic readings by about 10 mmHg. It also outperformed other add-on drugs on ambulatory measures.8PubMed Central. Clinical efficacy and safety of spironolactone in patients with resistant hypertension: A systematic review and meta-analysis The reason spironolactone works so well here is that a substantial share of resistant hypertension is driven by excess aldosterone activity, even in people who have not been formally diagnosed with an aldosterone-producing adrenal tumor.
A more recent randomized trial compared spironolactone head-to-head with amiloride, a potassium-sparing diuretic that works through a different mechanism, and found that amiloride was not inferior: both drugs dropped home systolic blood pressure by about 14 to 15 mmHg from baseline, with no meaningful difference between them.9JAMA. Spironolactone vs Amiloride for Resistant Hypertension: A Randomized Clinical Trial This matters because amiloride does not carry the hormonal side effects of spironolactone, giving clinicians another option for patients who cannot tolerate breast tenderness or other androgen-related issues.
Chronic Kidney Disease With Type 2 Diabetes
Finerenone has carved out a distinct role in protecting the kidneys and heart in people with type 2 diabetes and chronic kidney disease. The FIDELIO-DKD trial followed over 5,600 patients for a median of about two and a half years and found that finerenone reduced a composite kidney outcome by 18% compared with placebo. It also reduced cardiovascular events.10PubMed. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes 11PubMed Central. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
When data from the two major finerenone trials were pooled in the FIDELITY analysis, the kidney benefits held up convincingly. The composite kidney outcome, which included kidney failure and sustained large drops in kidney function, was reduced by 23%. The risk of a sustained large decline in kidney filtration rate specifically was cut by 30%, and progression to end-stage kidney disease was reduced by 20%.12European Heart Journal. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis These results established finerenone as the first MRA with robust evidence for slowing kidney disease progression in this specific population, and it is now included in clinical guidelines for diabetic kidney disease management.
Liver Cirrhosis and Ascites
In liver cirrhosis, the body’s hormonal response to poor liver function drives sodium and water retention, producing ascites, the uncomfortable and sometimes dangerous accumulation of fluid in the abdomen. Spironolactone has been a cornerstone of ascites management for decades, often paired with a loop diuretic. A comparative study found eplerenone to be equally effective for managing ascites, with a better side-effect profile.13European Journal of Gastroenterology & Hepatology. Comparative study of spironolactone and eplerenone in management of ascites in patients of cirrhosis of liver Still, spironolactone remains the default in most clinical practice for ascites because of its lower cost and long track record.
Antiandrogenic Uses of Spironolactone
Because spironolactone blocks androgen receptors and lowers testosterone production, it has a long history of off-label use for conditions driven by excess androgen activity. The most common is hirsutism, the growth of coarse, dark facial and body hair in women. At doses of 100 to 200 mg daily, spironolactone has been shown to slow hair growth, decrease hair shaft diameter, and halt the progression of darkening and coarsening. In one study of 20 women with moderate to severe hirsutism, 19 had clear improvement, with changes visible within two months and maximal effects at six months.14JAMA. Treatment of Hirsutism With Spironolactone The drug proved equally effective regardless of whether the hirsutism was associated with polycystic ovary syndrome or had no identifiable hormonal cause.15PubMed. Use of spironolactone in treatment of hirsutism
Dermatologists also prescribe spironolactone for hormonal acne in women, particularly acne that clusters along the jawline and flares around menstrual periods. It is increasingly used as part of gender-affirming hormone therapy for transgender women, where its androgen-blocking properties complement estrogen treatment. None of these uses appear on spironolactone’s original label as a diuretic, but they are well-established in clinical practice.
Side Effects
The side effects of MRAs cluster into two main concerns: elevated potassium and hormonal effects. Understanding both is important for anyone taking or considering these drugs.
Hyperkalemia
Because MRAs block aldosterone’s signal telling the kidneys to excrete potassium, potassium levels rise. This is the most clinically significant side effect. A meta-analysis of placebo-controlled trials found that hyperkalemia occurred in about 9% of patients on an MRA versus about 4% on placebo. Spironolactone was associated with a higher rate than eplerenone: roughly 17.5% versus 5% in the respective trial populations.16PubMed. True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis About half of the hyperkalemia events attributed to MRA use may actually not be caused by the drug, as the meta-analysis estimated that 46% of cases were unrelated to MRA treatment.
In real-world practice, the numbers can be higher, particularly in people with heart failure. One large observational study found that about 18.5% of new MRA users experienced at least one episode of elevated potassium within a year, and in heart failure patients specifically, the rate was over 26%. Most episodes happened in the first three months.17European Journal of Heart Failure. Incidence, Predictors and Clinical Management of Hyperkalaemia in New Users of Mineralocorticoid Receptor Antagonists Kidney function is the strongest predictor of risk. A study of MRA users stratified by kidney filtration rate found elevated hyperkalemia hazard ratios at every level of kidney function, with the highest risk paradoxically appearing in those with better kidney function compared to their respective non-MRA-using controls, though the absolute risk is highest when kidneys are already impaired.18PubMed Central. Mineralocorticoid receptor antagonist treatment in patients with renal insufficiency and the associated risk of hyperkalemia and death
Mild potassium elevations are usually manageable with dose adjustments, dietary changes, or the addition of a potassium-binding medication. Severe hyperkalemia, however, can cause dangerous heart rhythm disturbances. This is why regular blood work to check potassium and kidney function is standard practice during MRA therapy, especially in the first weeks and after any dose change.
Hormonal Side Effects
Spironolactone’s affinity for androgen and progesterone receptors causes side effects that the other MRAs largely avoid. In men, the most talked-about side effect is gynecomastia, which is breast tissue growth that can be painful. It is dose-dependent and generally reversible after stopping the drug. Eplerenone and finerenone cause gynecomastia rarely if at all, because they do not meaningfully bind androgen receptors. In women, spironolactone can cause menstrual irregularities and breast tenderness. These hormonal effects are the main reason many patients switch from spironolactone to eplerenone or finerenone, or why clinicians start with eplerenone for male patients who need an MRA for heart failure.
Monitoring and Staying Safe on MRAs
Given the hyperkalemia risk, close monitoring is not optional. Your doctor will typically check potassium and kidney function within a week or two of starting an MRA and again after any dose change. Once stable, checks every few months are standard. If your potassium starts creeping up, the usual response is to reduce the MRA dose, add a potassium binder, or restrict high-potassium foods. Bananas get all the attention, but potatoes, tomatoes, oranges, and many salt substitutes are actually larger contributors to dietary potassium intake for most people.
A prospective study tested whether a structured multidisciplinary approach could make MRA therapy safer. Patients at risk for hyperkalemia who received a combination of dietitian-led potassium restriction, remote monitoring, and potassium binder use were nearly five times more likely to reach their optimal MRA dose compared with matched controls. They also had fewer heart failure hospitalizations.19PubMed Central. Optimizing Mineralocorticoid Receptor Antagonist Therapy in Heart Failure Through Integrated Care Strategies The takeaway is that hyperkalemia risk does not have to mean MRA avoidance; it means MRA use with proper support.
Who Should Not Take MRAs
The clearest contraindication is pregnancy. All drugs that interfere with the renin-angiotensin-aldosterone system, including MRAs, are teratogenic and contraindicated in pregnant women.20PubMed Central. Review of Cardiovascular Drugs in Pregnancy Women of childbearing potential who take spironolactone for acne or hirsutism should use reliable contraception.
Severe kidney dysfunction is the other major barrier. In a community-based study of heart failure patients, the most commonly documented contraindication to MRA therapy was poor kidney function, followed by existing hyperkalemia and low blood pressure.21PubMed Central. Obstacles to mineralocorticoid receptor antagonists in a community‐based heart failure population In practice, this means many patients who could benefit from an MRA never receive one. The formal cutoff typically cited is a kidney filtration rate below 30, but even patients between 30 and 45 require careful monitoring. Addison’s disease, where the adrenal glands already produce too little aldosterone, is another absolute contraindication.
Drug Interactions Worth Knowing About
The most important drug interactions with MRAs involve medications that also raise potassium. ACE inhibitors, ARBs (angiotensin receptor blockers), and potassium supplements all push potassium levels up, and combining them with an MRA amplifies the risk. This does not mean the combination is avoided; in heart failure, MRAs are routinely prescribed alongside ACE inhibitors or ARBs. It just means the monitoring needs to be tighter.
On the metabolic side, eplerenone and finerenone are processed by the liver enzyme CYP3A4. Drugs that strongly inhibit this enzyme, such as certain antifungals and some HIV medications, can dramatically increase MRA blood levels and raise hyperkalemia risk. Spironolactone is the exception here, as it does not rely on CYP3A4 for its metabolism.22PubMed Central. Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: Clinical Evidence, Pharmacology, and Drug-Drug Interactions for Personalized Management of Hyperkalemia If you take a strong CYP3A4 inhibitor for another condition, your doctor may favor spironolactone over eplerenone or finerenone for exactly this reason. Grapefruit juice, a well-known CYP3A4 inhibitor, is generally not potent enough to cause clinically important interactions at normal consumption levels, but large quantities could theoretically matter with eplerenone.
How MRAs Came to Exist
The path to modern MRAs began with animal experiments in the 1930s and 1940s. Researchers in 1938 demonstrated that dogs treated with a precursor hormone to aldosterone retained sodium and lost potassium. By 1943, experiments in rats showed that the combination of this hormone and a high-salt diet produced malignant hypertension along with inflammation and fibrosis across multiple organs, including the heart and kidneys.23European Heart Journal. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine These animal models established that the damage was not simply from high blood pressure but from the inflammatory and fibrotic effects of aldosterone receptor activation, an insight that remains central to the rationale for MRAs today.
In 1957, the first steroidal aldosterone antagonists were synthesized, but they had to be injected. Spironolactone, an oral version with far greater potency, was synthesized the same year and approved by the FDA within three years. For decades it was used mainly as a mild diuretic. The pivotal RALES trial in 1999, which showed that adding spironolactone to standard therapy cut mortality by 30% in severe heart failure, transformed MRAs from niche diuretics into essential cardiovascular drugs. Eplerenone followed, and finerenone extended the class into cardiorenal territory. The field continues to evolve: multiple nonsteroidal MRAs beyond finerenone are in development, with the goal of maximizing organ protection while minimizing potassium risk and hormonal side effects.
Why Many Eligible Patients Never Get Prescribed an MRA
Despite strong evidence, MRAs remain underused. Studies of heart failure populations consistently find that a large share of patients who meet guideline criteria for an MRA never receive a prescription. Fear of hyperkalemia is the dominant driver. Clinicians see the potassium risk and decide the monitoring burden is too high, especially for older patients or those with even mildly reduced kidney function. The community-based study mentioned earlier found that kidney dysfunction was the most frequently cited reason for withholding MRA therapy, yet many of the patients flagged as contraindicated actually had filtration rates above the formal cutoff and could have been treated with careful monitoring.21PubMed Central. Obstacles to mineralocorticoid receptor antagonists in a community‐based heart failure population
The emergence of potassium binders and remote-monitoring tools has shifted this calculus. When hyperkalemia can be caught early through telemedicine alerts and managed proactively with diet and binders, the population of patients who can safely tolerate MRAs grows substantially. The gap between who should receive an MRA and who actually does is one of the persistent quality-of-care issues in cardiology, and newer tools may finally help close it.